Down‐regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer

p21 (CDKN1A/CIP1/WAF1), one of the cyclin‐dependent kinase inhibitors, plays a key role in regulating the cell cycle and is transcriptionally regulated by p53. Down‐regulation of p21 is caused by TP53 mutations in colorectal cancer. CpG island methylator phenotype (CIMP) appears to be a distinct subtype of colorectal cancer with concordant methylation of multiple gene promoters and is associated with a high degree of microsatellite instability (MSI‐H) and BRAF mutations. However, no study to date has evaluated the relationship between p21 expression and CIMP in colorectal cancer. The purpose of this study was to examine the inter‐relationships between p21, p53, CIMP, MSI and KRAS/BRAF status in colorectal cancer. We utilized 737 relatively unbiased samples of colorectal cancers from two large prospective cohort studies. Using quantitative real‐time PCR (MethyLight), we measured DNA methylation in five CIMP‐specific gene promoters [CACNA1G, CDKN2A (p16/INK4A), CRABP1, MLH1 and NEUROG1]. CIMP‐high (≥4/5 methylated promoters) was diagnosed in 118 (16%) of the 737 tumours. We also assessed expression of p21 and p53 by immunohistochemistry. Among the 737 tumours, 371 (50%) showed p21 loss. Both p21 loss and p53 positivity were inversely associated with CIMP‐high, MSI‐H and BRAF mutations. The associations of p21 with these molecular features were still present after tumours were stratified by p53 status. In contrast, the associations of p53 positivity with the molecular features were no longer present after tumours were stratified by p21 status. When CIMP‐high and non‐CIMP‐high tumours were stratified by MSI or KRAS/BRAF status, CIMP‐high and MSI‐H (but not BRAF mutations) were still inversely associated with p21 loss. In conclusion, down‐regulation of p21 is inversely correlated with CIMP‐high and MSI‐H in colorectal cancer, independent of TP53 and BRAF status. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  M. Loda,et al.  CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. , 2006, The Journal of molecular diagnostics : JMD.

[2]  M. Loda,et al.  Correlation of Pathologic Features With CpG Island Methylator Phenotype (CIMP) by Quantitative DNA Methylation Analysis in Colorectal Carcinoma , 2006, The American journal of surgical pathology.

[3]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[4]  S. Kakar,et al.  BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non‐mucinous colorectal cancer , 2006, International journal of cancer.

[5]  M. Loda,et al.  Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. , 2006, Neoplasia.

[6]  Shuji Ogino,et al.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. , 2006, The Journal of molecular diagnostics : JMD.

[7]  P. Hall,et al.  Assessing p53 in clinical contexts: unlearned lessons and new perspectives , 2006, The Journal of pathology.

[8]  三谷 佳嗣.  Histone H3 acetylation is associated with reduced p21WAF1/CIP1 expression by gastric carcinoma , 2006 .

[9]  N. Goldstein.  Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. , 2006, American journal of clinical pathology.

[10]  M. Loda,et al.  Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component , 2006, Modern Pathology.

[11]  W. Willett,et al.  Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. , 2005, Journal of the National Cancer Institute.

[12]  C. Cinti,et al.  Modulation of cell cycle components by epigenetic and genetic events. , 2005, Seminars in oncology.

[13]  E. Giovannucci,et al.  DNA methylation, field effects, and colorectal cancer. , 2005, Journal of the National Cancer Institute.

[14]  Gary L Rosner,et al.  Tumour vasculature: On the verge of collapse , 2005, Nature Reviews Cancer.

[15]  Shuji Ogino,et al.  Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[16]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[17]  M. Loda,et al.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.

[18]  J. Jass.  Serrated adenoma of the colorectum and the DNA-methylator phenotype , 2005, Nature Clinical Practice Oncology.

[19]  Graham A. Colditz,et al.  The Nurses' Health Study: lifestyle and health among women , 2005, Nature Reviews Cancer.

[20]  Geng-Hung Liu,et al.  p21 stability: linking chaperones to a cell cycle checkpoint. , 2005, Cancer cell.

[21]  Brian J. Smith,et al.  Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. , 2005, Molecular cell.

[22]  Y. Mitani,et al.  Histone H3 acetylation is associated with reduced p21WAF1/CIP1 expression by gastric carcinoma , 2005, The Journal of pathology.

[23]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[24]  R. Holubkov,et al.  p53 Alterations in Colon Tumors: A Comparison of SSCP/Sequencing and Immunohistochemistry , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[25]  Jian Yu,et al.  Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. , 2004, World Journal of Gastroenterology.

[26]  N. Matsubara,et al.  Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Issa,et al.  CpG island methylation in gastroenterologic neoplasia: a maturing field. , 2004, Gastroenterology.

[28]  M. Widschwendter,et al.  Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. , 2004, Clinical chemistry.

[29]  Yingxuan Chen,et al.  Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. , 2004, World journal of gastroenterology.

[30]  J. Houghton,et al.  P21Cip1 Is a Critical Mediator of the Cytotoxic Action of Thymidylate Synthase Inhibitors in Colorectal Carcinoma Cells , 2004, Cancer Research.

[31]  N. Matsubara,et al.  BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum , 2004, Gut.

[32]  Martin Widschwendter,et al.  Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.

[33]  Hanako Kobayashi,et al.  Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells , 2004, International journal of cancer.

[34]  C. Plass,et al.  SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Iacopetta,et al.  Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands , 2002, Gut.

[36]  J. Issa,et al.  CpG island methylation in aberrant crypt foci of the colorectum. , 2002, The American journal of pathology.

[37]  R. Ward,et al.  CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. , 2002, Gastroenterology.

[38]  Jeffrey S. Morris,et al.  Concordant CpG island methylation in hyperplastic polyposis. , 2002, The American journal of pathology.

[39]  B. Iacopetta,et al.  Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. , 2001, Cancer letters.

[40]  M. Leppert,et al.  Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. , 2001, The American journal of pathology.

[41]  J. Palazzo,et al.  Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. , 2000, Human pathology.

[42]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[43]  N. Ahuja,et al.  Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Hsieh,et al.  Adenovirus-Mediated p21(WAF1/SDII/CIP1)Gene Transfer Induces Apoptosis of Human Cervical Cancer Cell Lines , 1999, Journal of Virology.

[46]  P. Laird,et al.  CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. , 1999, Cancer research.

[47]  F. Sinicrope,et al.  Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  M. Gorospe,et al.  p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. , 1997, Oncogene.

[49]  B. Vogelstein,et al.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms , 1994, The Journal of pathology.